|
Sacituzumab govitecan-hziy Clinical Trials
5 actively recruiting trials across 5 locations
No change since May 2026
Also known as: GS-0132, IMMU-132, Trodelvy, Trodelvy™
Pipeline
Phase 1: 1Phase 2: 3Phase 1/2: 1
Top Sponsors
- Gilead Sciences2
- Memorial Sloan Kettering Cancer Center1
- Georgetown University1
- Avenzo Therapeutics, Inc.1
Indications
- Cancer5
- Liver Disease1
- CCNE1 Amplification1
- Liver Failure1
- Advanced or Metastatic Solid Tumor1
Tucson, Arizona1 trial
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
The University of Arizona Cancer Center-North Campus
Phase 2
Long Beach, California1 trial
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Pacific Shores Medical Group
Phase 1
Palo Alto, California1 trial
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Stanford Cancer Institute
Phase 2
New Haven, Connecticut1 trial
Study of AVZO-021 in Patients With Advanced Solid Tumors
Yale Cancer Center
Phase 1/2
Basking Ridge, New Jersey1 trial
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Basking Ridge
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.